INO-5401 + INO-9012
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
BRCA1/2 Mutation
Conditions
BRCA1/2 Mutation
Trial Timeline
Apr 20, 2021 → Mar 1, 2027
NCT ID
NCT04367675About INO-5401 + INO-9012
INO-5401 + INO-9012 is a phase 1 stage product being developed by Inovio Pharmaceuticals for BRCA1/2 Mutation. The current trial status is active. This product is registered under clinical trial identifier NCT04367675. Target conditions include BRCA1/2 Mutation.
What happened to similar drugs?
0 of 1 similar drugs in BRCA1/2 Mutation were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04367675 | Phase 1 | Active |
Competing Products
1 competing product in BRCA1/2 Mutation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olaparib + Olaparib + Placebo + Placebo | AstraZeneca | Phase 3 | 40 |